Lp(a) is cardiology's big unmet need: common, causal, genetic — and until now untreatable. Statins, diet, and exercise barely touch it. That's about to change, and it's one of the most exciting stories in the whole field.
Elevated Lp(a) affects ~1 in 5 people and independently drives both heart attacks and aortic-valve stenosis — yet none of the standard levers move it. For years the only real options were apheresis (physically filtering it from the blood) in extreme cases, plus driving ApoB and blood pressure harder to compensate. PCSK9 inhibitors and niacin lower it modestly, but neither was designed for the job.
A wave of targeted drugs cut Lp(a) by 65–100%: pelacarsen (antisense; the Lp(a)HORIZON outcome trial reads out ~2025–26), olpasiran (siRNA; OCEAN(a)), lepodisiran, and even an oral option, muvalaplin. The one open question is the big one: does lowering Lp(a) actually cut events? The outcome trials will answer within a couple of years. Evidence ●●●○○ (huge lowering proven; outcome benefit not yet)
High Lp(a)? Control everything else — for now
If your Lp(a) is high, the practical move today is to drive every other risk factor down hard — ApoB, blood pressure, smoking, metabolic health — because those you can change. The targeted drugs are close, but until their outcome trials report, they aren't yet proven to prevent events.
The Cholesterol Guide